William Blair Estimates Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX) – William Blair issued their FY2025 earnings per share (EPS) estimates for Immunic in a note issued to investors on Monday, March 24th. William Blair analyst M. Minter forecasts that the company will post earnings of ($0.89) per share for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share.

Several other brokerages also recently commented on IMUX. D. Boral Capital reissued a “buy” rating and issued a $17.00 price objective on shares of Immunic in a research note on Wednesday, February 26th. StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Immunic in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Trading Up 3.3 %

IMUX stock opened at $1.24 on Wednesday. The stock has a market capitalization of $111.70 million, a P/E ratio of -1.01 and a beta of 1.89. The firm has a 50-day moving average price of $1.08 and a 200-day moving average price of $1.21. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Jane Street Group LLC increased its stake in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the period. HB Wealth Management LLC bought a new stake in Immunic in the fourth quarter valued at approximately $81,000. State Street Corp increased its position in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Immunic during the 3rd quarter worth approximately $50,000. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.